Global Congress on Sepsis & Wound Care [SWC 2025]

Biography

Dr Rob Scott is a Zimbabwean born physician and a graduate of University of Cape Town. Rob has held leadership positions in global Pharma for over thirty years. At Pfizer he developed Lipitor and Norvasc. He invented and developed the first commercially available Polypill - Caduet. At AtheroGenics, he conducted the first large cardiovascular outcomes study to be wholly performed by a small biotech. At Amgen, Rob accelerated and achieved first approval for a PCSK9i, Repatha. Rob was also successful in getting FDA approval for the heart failure drug, Corlanor, despite not having a single US subject in testing. Rob was a member of the FDA Cardiac and Renal Drug Advisory Committee from 2012 to 2016 and participated as a committee member fourteen times. Rob retired in 2020 as the Chief Medical Officer at Abbvie where he had responsibility for around 40 new molecular entities, four thousand people and a budget of close to two billion dollars. During his tenure, Abbvie achieved over 14 major regulatory approvals including Venclexta, Orilissa, Skyrizi and Rinvoq. He also created the Development Design Center, a Center of Excellence focused on using AI, predictive analytics and big data to design and implement better clinical trials. He has been a board member of Transcelerate and the PhRMA R&D Leadership Forum. Rob is a leader in digital transformation of clinical research including a broad range of aspects from AI, predictive analytics, innovative program and study design, synthetic and historical controls, pragmatic and real world studies, use of passive data collection using IoT and wearables and risk based monitoring to name a few. Rob is currently on the board of ArisGlobal, Confo Therapeutics, Draupnir Bio, Oncospherix, WindTree Therapeutics, Redx Pharma and Variant Bio. He is also on the scientific and strategic advisory boards of Variant Bio, Cytel, Inflexion, Orange Grove Bio, Channavix, Mineralys and BioEthics International.